Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Cain

Clinical Cardiac Electrophysiology Saint Helena, CA Medical Doctor

NPI 1912210931 CMS profile 503150

6 Woodland Rd Ste 304, Saint Helena, CA 94574

Open in the dashboard

General payments

$38,942

675 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Cain of Saint Helena, CA is reported in the CMS Open Payments database as having received $38,942 across 675 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,747 114
2024 General $6,370 142
2023 General $5,921 155
2022 General $5,839 122
2021 General $2,195 49
2020 General $1,220 32
2019 General $7,649 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Cain
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Matthew Cain were reported at $9,747. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Matthew Cain Clinical Cardiac Electrophysiology median Middle half National median
2019 $7,649 $2,361 $585–$8,260 $163
2020 $1,220 $993 $247–$4,351 $114
2021 $2,195 $1,185 $326–$4,739 $132
2022 $5,839 $2,073 $554–$6,789 $149
2023 $5,921 $2,568 $759–$8,159 $160
2024 $6,370 $2,557 $703–$7,403 $164
2025 $9,747 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $8,446 167 payments
  2. Medtronic Vascular, Inc. $6,616 41 payments
  3. Medtronic, Inc. $6,568 100 payments
  4. Abbott Laboratories $6,511 98 payments
  5. Biosense Webster, Inc. $4,870 188 payments
  6. Biotronik Inc. $2,910 34 payments
  7. Philips Electronics North America Corporation $835 4 payments
  8. Abiomed $631 11 payments
  9. Impulse Dynamics (USA) Inc. $287 3 payments
  10. Shockwave Medical, Inc $200 5 payments
  11. Other $1,069 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $27,995 639 payments
  2. Travel and Lodging $10,775 34 payments
  3. Education $171 2 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $3,251 105 payments
  2. FARAPULSE Farapulse_Rm $2,611 7 payments
  3. LINQ II $2,391 29 payments
  4. AVEIR $1,973 21 payments
  5. Acticor 7 VR-T DX $1,783 19 payments
  6. EVERA MRI XT DR SURESCAN $1,504 7 payments
  7. FARAPULSE Farapulse_Ep $1,081 17 payments
  8. Micra $1,027 22 payments
  9. AURORA EV-ICD MRI SURESCAN $761 7 payments
  10. Carto 3 System $746 31 payments
  11. Other $14,582 344 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,028

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$428,122

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

40%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 265 $308,259
Xarelto Rivaroxaban Brand 82 $103,856
Flecainide Acetate Generic 114 $5,375
Metoprolol Succinate Generic 89 $1,915
Amiodarone Hcl Generic 70 $1,696
Sotalol Sotalol Hcl Brand 41 $1,412
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 23 $1,146
Atorvastatin Calcium Generic 57 $1,059
Digoxin Generic 32 $853
Metoprolol Tartrate Generic 52 $512

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$349,621

Medicare's payments for the services billed

Medicare patients

1,395

Average age 77

Services billed

3,328

553 women, 842 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 67%
Heart failure 46%
Ischemic heart disease 46%
Arthritis 44%
Chronic kidney disease 32%
Diabetes 31%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $30
$30 — —
Repatha
  • Amgen Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

675 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record